Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody-Drug ConjugateMOLECULAR CANCER THERAPEUTICSIF5.52022-06-0617OAAI
Model-Informed Drug Development of the Masked Anti-PD-L1 Antibody CX-072CLINICAL PHARMACOLOGY & THERAPEUTICSIF5.52020-08-3114PREAI
Development of a probody drug conjugate (PDC) targeting CD71 for the treatment of solid tumors and lymphomasCANCER RESEARCHIF16.62016-07-154PRE
Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4MABSIF7.32014-10-2786OAAI
Transforming Notch ligands into tumor-antigen targets: A Probody-Drug Conjugate (PDC) targeting Jagged 1 and Jagged 2CANCER RESEARCHIF16.62014-10-017PRE
An anti-Jagged-1/-2 Probody demonstrates inhibition of Jagged-dependent Notch signaling and is activated in multiple types of tumorsCANCER RESEARCHIF16.62014-10-012PRE
Tumor-specific inhibition of jagged-dependent notch signaling using a Probody™ therapeutic.MOLECULAR CANCER THERAPEUTICSIF5.52013-11-016PRE
Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic IndexSCIENCE TRANSLATIONAL MEDICINEIF14.62013-10-16244PREAI
Development of a proteolytically activatable EGFR Probody for cancer therapyCANCER RESEARCHIF16.62013-04-011PRE
Final results from the Phase I study of MetMAb, a monovalent antagonist antibody to the receptor Met, dosed as single agent and in combination with bevacizumab in patients with advanced solid malignanciesCANCER RESEARCHIF16.62011-04-010PRE
Liver-specific activities of FGF19 require Klotho betaJOURNAL OF BIOLOGICAL CHEMISTRYIF3.92007-09-01280OAAI
Single prenyl-binding site on protein prenyl transferasesPROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICAIF9.11998-10-1327OAAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向